ClinicalTrials.gg
CompletedNCT00950300Updated Jan 23, 2018Results posted

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

A Phase 3 interventional study of 5-Fluorouracil and Cyclophosphamide in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 106 sites in 26 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-23.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
596
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
30th of 366
596 · median 61
Started
2009
with 16 others
Phase 3
60 of 374
3 open now
Registered
142nd of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 30th largest by enrollment of the 366 interventional ones that give a count, is one of 17 that started in 2009, is one of 60 in phase 3, and was the 142nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

In this open-label multicenter trial, participants with operable or locally advanced breast cancer will be randomized to pre-operative treatment with 8 cycles of chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil, epirubicin, and cyclophosphamide) concurrent with either SC Herceptin or IV Herceptin. After surgery, participants will receive a further 10 cycles of SC or IV Herceptin as per randomization to complete 1 year of treatment. All cycles will be 21 days in length. After the end of study treatment, participants will be followed for safety and efficacy for up to 5 years or until disease recurrence, whichever is earlier.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult women greater than or equal to (≥) 18 years of age
  • Non- primary invasive adenocarcinoma of the breast clinical stage I to IIIC, including inflammatory and multicentric/multifocal breast cancer, with tumor size ≥1 centimeter (cm) by ultrasound or ≥2 cm by palpation, centrally confirmed -positive (immunohistochemical score [IHC] 3+ or in situ hybridization [ISH]-positive)
  • At least 1 in breast or lymph nodes (≥1 cm by ultrasound or ≥2 cm by palpation), except for inflammatory carcinoma (T4d)
  • Baseline (LVEF) ≥55%
  • (ECOG) status of 0 or 1
  • Adequate organ function at Baseline

Exclusion criteria

Exclusion Criteria:

  • History of any prior (ipsilateral and/or contralateral) invasive breast carcinoma
  • Past or current history of malignant neoplasms, except for curatively treated basal and squamous cell carcinoma of the skin and in situ carcinoma of the cervix
  • disease
  • Any prior therapy with anthracyclines
  • Prior anti- therapy or biologic or immunotherapy
  • Serious cardiac illness
  • Pregnant or lactating women
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
596 participants (actual)

Study arms

  • Active comparator
    Herceptin IV + Chemotherapy

    Participants will receive Herceptin via IV infusion for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin IV will be given on Day 1 of each 21-day cycle, as 8 milligrams per kilogram (mg/kg) for a loading dose during Cycle 1 and as 6 mg/kg during subsequent cycles.

    Drug: 5-Fluorouracil · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Epirubicin · Drug: Herceptin IV [trastuzumab]

  • Experimental
    Herceptin SC + Chemotherapy

    Participants will receive Herceptin via SC injection for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin SC will be given on Day 1 of each 21-day cycle, as a 600-milligram (mg) fixed dose.

    Drug: 5-Fluorouracil · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Epirubicin · Drug: Herceptin SC [trastuzumab]

Interventions

  • Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m\^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.

  • Participants will receive cyclophosphamide, 500 mg/m\^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.

  • Participants will receive docetaxel, 75 mg/m\^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.

  • Participants will receive epirubicin, 75 mg/m\^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.

  • Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.

  • Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.

06

What researchers measure

Primary outcomes

  1. Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery

    Pre-dose samples were obtained prior to surgery (Cycle 8). The observed Ctrough was recorded, averaged among all participants, and expressed in micrograms per milliliter (μg/mL).

    Time frame: Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)

  2. Percentage of Participants With Pathological Complete Response (pCR)

    Participants were evaluated following eight cycles of treatment and after surgery to assess for pCR, defined as absence of neoplastic invasive cells in the breast according to pathologist examination. The percentage of participants with pCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.

    Time frame: After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)

Secondary outcomes

  1. Observed Ctrough of Trastuzumab After Surgery

    Pre-dose samples were obtained after surgery (Cycle 13). The observed Ctrough was recorded, averaged among all participants, and expressed in μg/mL.

    Time frame: Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)

  2. Predicted Ctrough of Trastuzumab Prior to Surgery

    Predicted Ctrough at pre-dose prior to surgery (Cycle 8) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL.

    Time frame: Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)

  3. Predicted Ctrough of Trastuzumab After Surgery

    Predicted Ctrough at pre-dose after surgery (Cycle 13) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL.

    Time frame: Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)

  4. Number of Participants With Ctrough of Trastuzumab >20 μg/mL Prior to Surgery

    Pre-dose samples were obtained prior to surgery (Cycle 8). The number of participants who had an observed Ctrough \>20 μg/mL was reported.

    Time frame: Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)

  5. Number of Participants With Ctrough of Trastuzumab >20 μg/mL After Surgery

    Pre-dose samples were obtained after surgery (Cycle 13). The number of participants who had an observed Ctrough \>20 μg/mL was reported.

    Time frame: Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)

  6. Maximum Serum Concentration (Cmax) of Trastuzumab Prior to Surgery

    PK samples were obtained prior to surgery (Cycle 7). The Cmax during Cycle 7 was recorded, averaged among all participants, and expressed in μg/mL.

    Time frame: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)

  7. Time of Maximum Serum Concentration (Tmax) of Trastuzumab Prior to Surgery

    PK samples were obtained prior to surgery (Cycle 7). The Tmax during Cycle 7 was recorded, averaged among all participants, and expressed in days.

    Time frame: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)

  8. Area Under the Concentration-Time Curve From 0 to 21 Days (AUC21d) of Trastuzumab Prior to Surgery

    PK samples were obtained prior to surgery (Cycle 7). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 7 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in days multiplied by micrograms per milliliters (d\*μg/mL).

    Time frame: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)

  9. Cmax of Trastuzumab After Surgery

    PK samples were obtained after surgery (Cycle 12). The Cmax during Cycle 12 was recorded, averaged among all participants, and expressed in μg/mL.

    Time frame: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)

  10. Tmax of Trastuzumab After Surgery

    PK samples were obtained after surgery (Cycle 12). The Tmax during Cycle 12 was recorded, averaged among all participants, and expressed in days.

    Time frame: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)

  11. AUC21d of Trastuzumab After Surgery

    PK samples were obtained after surgery (Cycle 12). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 12 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in d\*μg/mL.

    Time frame: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)

  12. Percentage of Participants With Total Pathological Complete Response (tpCR)

    Participants were evaluated following eight cycles of treatment and after surgery to assess for tpCR, defined as absence of neoplastic invasive cells in the breast and axillary lymph nodes according to pathologist examination. The percentage of participants with tpCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.

    Time frame: After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)

  13. Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, Among Those With Measurable Disease at Baseline

    Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to less than (\<) 10 millimeters (mm) with no prior assessment of progressive disease (PD). PR was defined as greater than or equal to (≥) 30% decrease from Baseline in sum diameter (SD) of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. The percentage of participants with overall response of CR or PR at the end of neoadjuvant treatment was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.

    Time frame: Tumor assessments at Baseline; on Day 1 of Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months overall)

  14. Time to Response According to RECIST Version 1.0, Among Those With Measurable Disease at Baseline

    Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to \<10 mm with no prior assessment of PD. PR was defined as ≥30% decrease from Baseline in SD of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. Time to response was defined as the time from first dose of study medication to the first assessment of CR or PR, which was the date the response was first documented by objective evidence, among participants with an overall response of CR or PR.

    Time frame: Tumor assessments at Baseline; on Day 1 Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of chemotherapy (approximately 6 months overall)

  15. Percentage of Participants Who Experienced a Protocol-Defined Event

    Protocol-defined events included disease recurrence/progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. The percentage of participants who experienced a protocol-defined event at any time during the study was reported.

    Time frame: Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)

  16. Event-Free Survival (EFS)

    Protocol-defined events included disease recurrence or progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. EFS was estimated by Kaplan-Meier analysis and defined as the time from randomization to the first protocol-defined event.

    Time frame: Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)

  17. Percentage of Participants Who Died

    The percentage of participants who died at any time during the study was reported.

    Time frame: Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)

  18. Overall Survival (OS)

    OS was estimated by Kaplan-Meier analysis and defined as the time from randomization to death from any cause.

    Time frame: Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)

  19. Number of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab

    Participants provided PK samples for evaluation of anti-trastuzumab antibodies. The number of participants with "Treatment-induced ADAs" and "Treatment-enhanced ADA" against trastuzumab at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer).

    Time frame: Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18

  20. Number of Participants With ADAs Against Recombinant Human Hyaluronidase (rHuPH20)

    Participants in the Herceptin SC arm provided PK samples for evaluation of anti-rHuPH20 antibodies. The number of participants with "Treatment-induced ADAs" and "Treatment-enhanced ADA" against rHuPH20 (an excipient unique to the SC formulation) at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer).

    Time frame: Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18

07

Results

Posted Jan 23, 2017

Participant flow

Neoadjuvant/Adjuvant Treatment Periods
Participant flow — Neoadjuvant/Adjuvant Treatment Periods
MilestoneHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Started299297
Received neoadjuvant treatment298297
Underwent surgery277273
Entered adjuvant treatment277274
Completed257255
Not completed4242
Withdrew: Adverse event or intercurrent illness615
Withdrew: Death13
Withdrew: Insufficient therapeutic response30
Withdrew: Violation of selection criteria21
Withdrew: Protocol violation10
Withdrew: Participant refusal/withdrawal45
Withdrew: Lost to follow-up21
Withdrew: Progression of disease1211
Withdrew: Recurrence of disease105
Withdrew: Other11
TFFU Period
Participant flow — TFFU Period
MilestoneHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Started265268
Completed165161
Not completed100107
Withdrew: Adverse event or intercurrent illness34
Withdrew: Death41
Withdrew: Refused treatment1011
Withdrew: Failure to return1616
Withdrew: Recurrence of disease6372
Withdrew: Other43
SFU Period
Participant flow — SFU Period
MilestoneHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Started118123
Completed4045
Not completed7878
Withdrew: Death4442
Withdrew: Lost to follow-up3028
Withdrew: Withdrawal by subject48

Outcome measures

PrimaryObserved Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery

Pre-dose samples were obtained prior to surgery (Cycle 8). The observed Ctrough was recorded, averaged among all participants, and expressed in micrograms per milliliter (μg/mL).

Time frame:
Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Reported as:
Mean · μg/mL
Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery
μg/mLHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery57.8 ± 30.378.7 ± 43.9
Statistical analysis
  • Herceptin IV + Chemotherapy vs Herceptin SC + Chemotherapy · Geometric mean ratio: 1.33 · 90% CI 1.24 to 1.44Ratio of test treatment group (Herceptin SC + Chemotherapy) to reference treatment group (Herceptin IV + Chemotherapy).
PrimaryPercentage of Participants With Pathological Complete Response (pCR)

Participants were evaluated following eight cycles of treatment and after surgery to assess for pCR, defined as absence of neoplastic invasive cells in the breast according to pathologist examination. The percentage of participants with pCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.

Time frame:
After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)
Reported as:
Number · percentage of participants
Percentage of Participants With Pathological Complete Response (pCR)
percentage of participantsHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Percentage of Participants With Pathological Complete Response (pCR)40.7 (34.7 to 46.9)45.4 (39.2 to 51.7)
Statistical analysis
  • Herceptin IV + Chemotherapy vs Herceptin SC + Chemotherapy · Difference in response rates: 4.70The one-sided 97.5% CI for the difference in response (pCR) rates was calculated using the Anderson-Hauck continuity correction.
SecondaryObserved Ctrough of Trastuzumab After Surgery

Pre-dose samples were obtained after surgery (Cycle 13). The observed Ctrough was recorded, averaged among all participants, and expressed in μg/mL.

Time frame:
Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Reported as:
Mean · μg/mL
Observed Ctrough of Trastuzumab After Surgery
μg/mLHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Observed Ctrough of Trastuzumab After Surgery62.1 ± 37.190.4 ± 41.9
Statistical analysis
  • Herceptin IV + Chemotherapy vs Herceptin SC + Chemotherapy · Geometric mean ratio: 1.51 · 90% CI 1.40 to 1.63Ratio of test treatment group (Herceptin SC + Chemotherapy) to reference treatment group (Herceptin IV + Chemotherapy).
SecondaryPredicted Ctrough of Trastuzumab Prior to Surgery

Predicted Ctrough at pre-dose prior to surgery (Cycle 8) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL.

Time frame:
Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Reported as:
Mean · μg/mL
Predicted Ctrough of Trastuzumab Prior to Surgery
μg/mLHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Predicted Ctrough of Trastuzumab Prior to Surgery51.4 ± 19.480.3 ± 33.2
Statistical analysis
  • Herceptin IV + Chemotherapy vs Herceptin SC + Chemotherapy · Geometric mean ratio: 1.55 · 90% CI 1.46 to 1.64Ratio of test treatment group (Herceptin SC + Chemotherapy) to reference treatment group (Herceptin IV + Chemotherapy).
SecondaryPredicted Ctrough of Trastuzumab After Surgery

Predicted Ctrough at pre-dose after surgery (Cycle 13) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL.

Time frame:
Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Reported as:
Mean · μg/mL
Predicted Ctrough of Trastuzumab After Surgery
μg/mLHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Predicted Ctrough of Trastuzumab After Surgery51.7 ± 20.080.6 ± 33.4
Statistical analysis
  • Herceptin IV + Chemotherapy vs Herceptin SC + Chemotherapy · Geometric mean ratio: 1.55 · 90% CI 1.45 to 1.64Ratio of test treatment group (Herceptin SC + Chemotherapy) to reference treatment group (Herceptin IV + Chemotherapy).
SecondaryNumber of Participants With Ctrough of Trastuzumab >20 μg/mL Prior to Surgery

Pre-dose samples were obtained prior to surgery (Cycle 8). The number of participants who had an observed Ctrough \>20 μg/mL was reported.

Time frame:
Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Reported as:
Number · participants
Number of Participants With Ctrough of Trastuzumab >20 μg/mL Prior to Surgery
participantsHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Number of Participants With Ctrough of Trastuzumab >20 μg/mL Prior to Surgery232227
SecondaryNumber of Participants With Ctrough of Trastuzumab >20 μg/mL After Surgery

Pre-dose samples were obtained after surgery (Cycle 13). The number of participants who had an observed Ctrough \>20 μg/mL was reported.

Time frame:
Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Reported as:
Number · participants
Number of Participants With Ctrough of Trastuzumab >20 μg/mL After Surgery
participantsHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Number of Participants With Ctrough of Trastuzumab >20 μg/mL After Surgery216227
SecondaryMaximum Serum Concentration (Cmax) of Trastuzumab Prior to Surgery

PK samples were obtained prior to surgery (Cycle 7). The Cmax during Cycle 7 was recorded, averaged among all participants, and expressed in μg/mL.

Time frame:
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Reported as:
Mean · μg/mL
Maximum Serum Concentration (Cmax) of Trastuzumab Prior to Surgery
μg/mLHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Maximum Serum Concentration (Cmax) of Trastuzumab Prior to Surgery221 ± 118149 ± 64.8
SecondaryTime of Maximum Serum Concentration (Tmax) of Trastuzumab Prior to Surgery

PK samples were obtained prior to surgery (Cycle 7). The Tmax during Cycle 7 was recorded, averaged among all participants, and expressed in days.

Time frame:
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Reported as:
Mean · days
Time of Maximum Serum Concentration (Tmax) of Trastuzumab Prior to Surgery
daysHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Time of Maximum Serum Concentration (Tmax) of Trastuzumab Prior to Surgery0.05 ± 0.044.12 ± 2.91
SecondaryArea Under the Concentration-Time Curve From 0 to 21 Days (AUC21d) of Trastuzumab Prior to Surgery

PK samples were obtained prior to surgery (Cycle 7). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 7 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in days multiplied by micrograms per milliliters (d\*μg/mL).

Time frame:
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Reported as:
Mean · d*μg/mL
Area Under the Concentration-Time Curve From 0 to 21 Days (AUC21d) of Trastuzumab Prior to Surgery
d*μg/mLHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Area Under the Concentration-Time Curve From 0 to 21 Days (AUC21d) of Trastuzumab Prior to Surgery2056 ± 5982268 ± 875
SecondaryCmax of Trastuzumab After Surgery

PK samples were obtained after surgery (Cycle 12). The Cmax during Cycle 12 was recorded, averaged among all participants, and expressed in μg/mL.

Time frame:
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Reported as:
Mean · μg/mL
Cmax of Trastuzumab After Surgery
μg/mLHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Cmax of Trastuzumab After Surgery230 ± 118166 ± 58.8
SecondaryTmax of Trastuzumab After Surgery

PK samples were obtained after surgery (Cycle 12). The Tmax during Cycle 12 was recorded, averaged among all participants, and expressed in days.

Time frame:
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Reported as:
Mean · days
Tmax of Trastuzumab After Surgery
daysHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Tmax of Trastuzumab After Surgery0.06 ± 0.134.08 ± 2.87
SecondaryAUC21d of Trastuzumab After Surgery

PK samples were obtained after surgery (Cycle 12). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 12 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in d\*μg/mL.

Time frame:
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Reported as:
Mean · d*μg/mL
AUC21d of Trastuzumab After Surgery
d*μg/mLHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
AUC21d of Trastuzumab After Surgery2179 ± 7252610 ± 945
SecondaryPercentage of Participants With Total Pathological Complete Response (tpCR)

Participants were evaluated following eight cycles of treatment and after surgery to assess for tpCR, defined as absence of neoplastic invasive cells in the breast and axillary lymph nodes according to pathologist examination. The percentage of participants with tpCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.

Time frame:
After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)
Reported as:
Number · percentage of participants
Percentage of Participants With Total Pathological Complete Response (tpCR)
percentage of participantsHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Percentage of Participants With Total Pathological Complete Response (tpCR)34.2 (28.5 to 40.3)39.2 (33.3 to 45.5)
Statistical analysis
  • Herceptin IV + Chemotherapy vs Herceptin SC + Chemotherapy · Difference in response rates: 5.01 · 95% CI -3.5 to 13.5The 95% CI for the difference in response (tpCR) rates was calculated using the Anderson-Hauck continuity correction.
SecondaryPercentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, Among Those With Measurable Disease at Baseline

Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to less than (\<) 10 millimeters (mm) with no prior assessment of progressive disease (PD). PR was defined as greater than or equal to (≥) 30% decrease from Baseline in sum diameter (SD) of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. The percentage of participants with overall response of CR or PR at the end of neoadjuvant treatment was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.

Time frame:
Tumor assessments at Baseline; on Day 1 of Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months overall)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, Among Those With Measurable Disease at Baseline
percentage of participantsHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, Among Those With Measurable Disease at Baseline88.8 (84.4 to 92.4)87.2 (82.5 to 91.0)
Statistical analysis
  • Herceptin IV + Chemotherapy vs Herceptin SC + Chemotherapy · Difference in response rates: -1.64 · 95% CI -7.4 to 4.2The 95% CI for the difference in response (CR+PR) rates was calculated using the Anderson-Hauck continuity correction.
  • Herceptin IV + Chemotherapy vs Herceptin SC + Chemotherapy · Odds ratio (or): 0.86 · 95% CI 0.50 to 1.46OR of test treatment group (Herceptin SC + Chemotherapy) to reference treatment group (Herceptin IV + Chemotherapy).
SecondaryTime to Response According to RECIST Version 1.0, Among Those With Measurable Disease at Baseline

Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to \<10 mm with no prior assessment of PD. PR was defined as ≥30% decrease from Baseline in SD of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. Time to response was defined as the time from first dose of study medication to the first assessment of CR or PR, which was the date the response was first documented by objective evidence, among participants with an overall response of CR or PR.

Time frame:
Tumor assessments at Baseline; on Day 1 Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of chemotherapy (approximately 6 months overall)
Reported as:
Median · weeks
Time to Response According to RECIST Version 1.0, Among Those With Measurable Disease at Baseline
weeksHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Time to Response According to RECIST Version 1.0, Among Those With Measurable Disease at Baseline6.14 (3 to 25)6.14 (3 to 28)
SecondaryPercentage of Participants Who Experienced a Protocol-Defined Event

Protocol-defined events included disease recurrence/progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. The percentage of participants who experienced a protocol-defined event at any time during the study was reported.

Time frame:
Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced a Protocol-Defined Event
percentage of participantsHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Percentage of Participants Who Experienced a Protocol-Defined Event33.332.7
SecondaryEvent-Free Survival (EFS)

Protocol-defined events included disease recurrence or progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. EFS was estimated by Kaplan-Meier analysis and defined as the time from randomization to the first protocol-defined event.

Time frame:
Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Reported as:
Median · months
Event-Free Survival (EFS)
monthsHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Event-Free Survival (EFS)NA (1 to 82)NA (1 to 76)
Statistical analysis
  • Herceptin IV + Chemotherapy vs Herceptin SC + Chemotherapy · Log Rank · p = 0.8651 · Hazard ratio (hr): 0.98 · 95% CI 0.74 to 1.29HR of test treatment group (Herceptin SC + Chemotherapy) to reference treatment group (Herceptin IV + Chemotherapy).
SecondaryPercentage of Participants Who Died

The percentage of participants who died at any time during the study was reported.

Time frame:
Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Percentage of Participants Who Died14.513.6
SecondaryOverall Survival (OS)

OS was estimated by Kaplan-Meier analysis and defined as the time from randomization to death from any cause.

Time frame:
Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Reported as:
Median · months
Overall Survival (OS)
monthsHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Overall Survival (OS)NA (2 to 82)NA (3 to 79)
Statistical analysis
  • Herceptin IV + Chemotherapy vs Herceptin SC + Chemotherapy · Log Rank · p = 0.7767 · Hazard ratio (hr): 0.94 · 95% CI 0.61 to 1.45HR of test treatment group (Herceptin SC + Chemotherapy) to reference treatment group (Herceptin IV + Chemotherapy).
SecondaryNumber of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab

Participants provided PK samples for evaluation of anti-trastuzumab antibodies. The number of participants with "Treatment-induced ADAs" and "Treatment-enhanced ADA" against trastuzumab at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer).

Time frame:
Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18
Reported as:
Number · participants
Number of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab
participantsHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Treatment-induced ADAs2846
Treatment-enhanced ADA21
SecondaryNumber of Participants With ADAs Against Recombinant Human Hyaluronidase (rHuPH20)

Participants in the Herceptin SC arm provided PK samples for evaluation of anti-rHuPH20 antibodies. The number of participants with "Treatment-induced ADAs" and "Treatment-enhanced ADA" against rHuPH20 (an excipient unique to the SC formulation) at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer).

Time frame:
Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18
Reported as:
Number · participants
Number of Participants With ADAs Against Recombinant Human Hyaluronidase (rHuPH20)
participantsHerceptin SC + Chemotherapy
Treatment-induced ADA49
Treatment-enhanced ADA13

Adverse events

Collected over Approximately 87 months overall. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Herceptin IV + Chemotherapy—45/298 (15.1%)277/298 (93%)
Herceptin SC + Chemotherapy—65/297 (21.9%)283/297 (95.3%)
Most frequent serious events
Showing 10 of 84
Most frequent serious events
EventHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
Febrile neutropeniaBlood and lymphatic system disorders10/29813/297
NeutropeniaBlood and lymphatic system disorders9/2987/297
PneumoniaInfections and infestations4/2982/297
Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2982/297
Cardiac failure congestiveCardiac disorders0/2982/297
TonsillitisInfections and infestations0/2982/297
CellulitisInfections and infestations0/2982/297
Lower respiratory tract infectionInfections and infestations0/2982/297
Postoperative wound infectionInfections and infestations0/2982/297
PyrexiaGeneral disorders0/2982/297
Most frequent other events
Showing 10 of 55
Most frequent other events
EventHerceptin IV + ChemotherapyHerceptin SC + Chemotherapy
AlopeciaSkin and subcutaneous tissue disorders188/298187/297
NauseaGastrointestinal disorders147/298145/297
NeutropeniaBlood and lymphatic system disorders135/298128/297
DiarrhoeaGastrointestinal disorders109/298101/297
FatigueGeneral disorders80/29870/297
AstheniaGeneral disorders75/29875/297
VomitingGastrointestinal disorders69/29869/297
MyalgiaMusculoskeletal and connective tissue disorders54/29861/297
ArthralgiaMusculoskeletal and connective tissue disorders60/29853/297
Decreased appetiteMetabolism and nutrition disorders59/29858/297

Baseline characteristics

Intent-to-Treat (ITT) Population: All participants with at least one efficacy assessment after administration of the first treatment cycle.

Age, Continuous
Age, Continuous(years)Herceptin IV + ChemotherapyHerceptin SC + ChemotherapyTotal
Mean49.5 ± 10.8350.3 ± 11.0849.9 ± 10.95
Sex: Female, Male
Sex: Female, Male(Participants)Herceptin IV + ChemotherapyHerceptin SC + ChemotherapyTotal
Female297294591
Male000
08

Study locations

106 sites
  • Centro Medico San Roque; Oncology Dept
    Tucuman, T4000IAK, Argentina
  • Caipo; Oncology
    Tucuman, T400IAK, Argentina
  • Hospital Sao Rafael - HSR
    Salvador, BA 41253-190, Brazil
  • Hospital das Clinicas - UFPR; Quimioterapia
    Curitiba, PR 80060-900, Brazil
  • Liga Norte Riograndense Contra O Câncer
    Natal, RN 59040150, Brazil
  • Clinica de Neoplasias Litoral
    Itajai, SC 88301-220, Brazil
  • Hospital Amaral Carvalho
    Jau, SP 17210-080, Brazil
  • Instituto do Cancer do Estado de Sao Paulo - ICESP
    Sao Paulo, SP 01246-000, Brazil
  • Hospital Perola Byington
    Sao Paulo, SP 01317-000, Brazil
  • Instituto de Oncologia de Sorocaba - CEPOS
    Sorocaba, SP 18030-245, Brazil
  • Hopital Maisonneuve- Rosemont; Oncology
    Montreal, Quebec H1T 2M4, Canada
  • CHU de Québec - Hôpital du Saint-Sacrement / ONCOLOGY
    Quebec, G1S 4L8, Canada
  • Hospital Universitario San Ignacio
    Bogota, 000472, Colombia
  • Grupo Salud Coop
    Bogota, Colombia
  • Oncólogos de Occidente
    Pereira, 600004, Colombia
  • Fakultni nemocnice Olomouc; Onkologicka klinika
    Olomouc, 779 00, Czechia
  • Krajska Nemocnice Pardubice Neurologicka Klinika
    Pardubice, 532 03, Czechia
  • Fakultni Thomayerova Nemocnice; Onkologicke Oddeleni
    Praha, 140 59, Czechia
  • Lekarske Fakulty Univerzity Karlovy Fakultni Nemocnice Na Bulovce; Ustav Radiacni Onkologie
    Praha, 180 81, Czechia
  • North Estonia Medical Centre Foundation; Oncology Centre
    Tallinn, 13419, Estonia
  • Tartu University Hospital; Clinic of Hematology and Oncology
    Tartu, 50406, Estonia
  • HOPITAL JEAN MINJOZ; Oncologie
    Besancon, 25030, France
  • Institut Daniel Hollard; Chimiotherapie Ambulatoire
    Grenoble, 38000, France
  • Hopital Albert Michallon; Oncologie
    La Tronche, 38700, France
  • Centre Jean Bernard
    Le Mans, 72015, France
  • Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset)
    Paris, 75475, France
  • Institut Jean Godinot; Hopital De Jour
    Reims, 51056, France
  • Centre Rene Huguenin; Medecine B
    St Cloud, 92210, France
  • CAMPUS CHARITÉ MITTE; Tagesklinik für Onkologie u.Hämatologie
    Berlin, 10117, Germany
  • Praxis Dr. Schoenegg
    Berlin, 10719, Germany
  • Johanniter GmbH; Johanniter-Krankenhaus; Internistische Onkologie
    Bonn, 53113, Germany
  • St. Johannes Hospital
    Dortmund, 44137, Germany
  • Gynaekologisch-Onkologische Schwerpunktpraxis Prof. Dr. med. Lueck, Dr. Schrader und Dr. Noeding
    Hannover, 30177, Germany
  • Sankt Elisabeth Krankenhaus; Gynaekology
    Leipzig, 04277, Germany
  • Klinik Lippe Lemgo; Frauenklinik
    Lemgo, 32657, Germany
  • Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe
    Offenbach, 63069, Germany
  • Klinik Obergöltzsch; Abt. Gynäkologie
    Rodewisch, 08228, Germany
  • Universitätsklinik Tübingen; Frauenklinik
    Tübingen, 72076, Germany
  • Centro Oncologico S.A.
    Guatemala, 01010, Guatemala
  • Queen Mary Hospital; Surgery
    Hong Kong, 852, Hong Kong
  • Semmelweis Egyetem Onkologiai Központ
    Budapest, 1083, Hungary
  • Hospital of Aladar Petz; Dept of Oncoradiology
    Gyor, 9023, Hungary
  • Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
    Szeged, 6720, Hungary
  • Hadassah Ein Karem Hospital; Oncology Dept
    Jerusalem, 9112001, Israel
  • Rabin Medical Center; Oncology Dept
    Petach Tikva, 49100, Israel
  • Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica
    Napoli, Campania 80131, Italy
  • ASST DI CREMONA; Dip. Medicina - S.C. Oncologia
    Cremona, Lombardia 26100, Italy
  • Fondazione Salvatore Maugeri; Servizio Di Prevenzione Oncologica
    Pavia, Lombardia 27100, Italy
  • Fondazione Salvatore Maugeri
    Pavia, Lombardia 27100, Italy
  • Gachon Medical School Gil Medical Center; Medical Oncology
    Incheon, 405-760, Korea, Republic of
  • Samsung Medical Centre; Division of Hematology/Oncology
    Seoul, 135-710, Korea, Republic of
  • Korea University Anam Hospital; Oncology Haemotology
    Seoul, 136-705, Korea, Republic of
  • Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology
    Seoul, 138-736, Korea, Republic of
  • Hospital Privado San Jose; Oncologia
    Obregon, 85000, Mexico
  • Centro Oncológico Estatal; ISSSEMYM Oncología
    Toluca, 50180, Mexico
  • Centro Oncologico America
    Panama, 0834-02723, Panama
  • Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology
    Arequipa, 04001, Peru
  • Hospital Nacional Edgardo Rebagliati Martins; Oncologia
    Lima, 11, Peru
  • Oncosalud Sac; Oncología
    Lima, 41, Peru
  • Unidad de Investigacion Oncologia Clinica - Piura; Unidad de Oncología Clínica
    Piura, 20011, Peru
  • Clinica Ricardo Palma
    San Isidro, Lima 27, Peru
  • Wojewodzki Szpital Zespolony; Oddział Onkologii
    Elblag, 82-300, Poland
  • COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej
    Lublin, 20-090, Poland
  • Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o.
    Olsztyn, 10-513, Poland
  • Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii
    Warszawa, 02-781, Poland
  • FSBI"National Medical Research Center of Oncology named after N.N.Petrov" MHRF
    St Petersburg, Leningrad 197758, Russian Federation
  • Ivanovo Regional Oncology Dispensary
    Ivanovo, 153040, Russian Federation
  • Blokhin Cancer Research Center; Combined Treatment
    Moscow, 115478, Russian Federation
  • Moscow city oncology hospital #62 of Moscow Healthcare Department
    Moscow, 143423, Russian Federation
  • State Budget Institution of Healthcare of Stavropol region Pyatigorsk Oncology Dispensary
    Pyatigorsk, 357502, Russian Federation
  • SBI for HPE "Ryazan State Medical University n.a. I.P. Pavlov" of MoH of RF
    Ryazan, 390011, Russian Federation
  • SBI of Healthcare Samara Regional Clinical Oncology Dispensary
    Samara, 443031, Russian Federation
  • Saratov Regional Clinical Hospital & Pathology Centre
    Saratov, 410053, Russian Federation
  • Saint-Petersburg City Clinical Oncology Dispensary
    St Petersburg, 197022, Russian Federation
  • SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary
    Stavropol, 355045, Russian Federation
  • Tula Regional Oncology Dispensary
    Tula, 300053, Russian Federation
  • GUZ Vladimir Regional Clinical Oncological Dispensary
    Vladimir, 600009, Russian Federation
  • Vychodoslovensky onkologicky ustav
    Kosice, 04001, Slovakia
  • Nzz - Oncology Outpatient Clinic
    Poprad, 05801, Slovakia
  • National Hospital; Oncotherapy Dept
    Bloemfontein, 9301, South Africa
  • Cancercare
    Cape Town, 7506, South Africa
  • Groote Schuur Hospital ( Uni of Capetown ); Oncology Dept
    Cape Town, 7506, South Africa
  • Wits Donald Gordon Clinical Trial Centre; Medical Oncology
    Parktown, Johannesburg, 2193, South Africa
  • Pretoria-East Hospital; 1 Sanwood Park
    Pretoria, 0081, South Africa
  • Rondebosch Oncology Centre
    Rondebosch, 7700, South Africa
  • Sandton Oncology Centre
    Sandton, 2196, South Africa
  • Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
    Santiago de Compostela, LA Coruña 15706, Spain
  • Hospital Universitari Sant Joan de Reus; Servicio de Oncologia
    Reus, Tarragona 43204, Spain
  • Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
    Madrid, 28007, Spain
  • Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
    Valencia, 46010, Spain
  • Hospital Universitario Miguel Servet; Servicio Oncologia
    Zaragoza, 50009, Spain
  • Skånes University Hospital, Skånes Department of Onclology
    Lund, 22185, Sweden
  • Akademiska sjukhuset, Onkologkliniken
    Uppsala, 75185, Sweden
  • Changhua Christian Hospital; Dept of Surgery
    Changhua, 500, Taiwan
  • Taipei Veterans General Hospital
    Taipei City, 112, Taiwan
  • Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology
    Taipei, 112, Taiwan
  • Chang Gung Medical Foundation-Taipei
    Taoyuan, 333, Taiwan
  • Chulalongkorn Hospital; Medical Oncology
    Bangkok, 10330, Thailand
  • National Cancer Inst.
    Bangkok, 10400, Thailand
  • Phramongkutklao Hospital;Dept Surgery/Surgical Oncology Unit
    Bangkok, 10400, Thailand

Showing the first 100 of 106 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC, Meyenberg C, Al-Sakaff N, Heinzmann D, Hegg R. Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial. JAMA Oncol. 2019 May 1;5(5):e190339. doi: 10.1001/jamaoncol.2019.0339. Epub 2019 May 9. PubMed 30998824 ↗
  • Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012 Sep;13(9):869-78. doi: 10.1016/S1470-2045(12)70329-7. Epub 2012 Aug 9. PubMed 22884505 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2009 to primary completion in Jul 2011, 20 months.

Results were first posted in Jan 2017, 5 years 6 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 20 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2009
First posted
Jul 31, 2009
StartActual
Oct 16, 2009
Primary completionActual
Jul 12, 2011
CompletionActual
Jan 24, 2017
Results first posted
Jan 23, 2017
Last update
Jan 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00950300
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 31, 2009
Start date
Oct 16, 2009
Primary completion
Jul 12, 2011
Completion
Jan 24, 2017
Results posted
Jan 23, 2017
Last update
Jan 23, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion